by John Conrad | Jun 28, 2024 | NewsBrief
AbbVie continues to bolster its immunology portfolio beyond Humira, announcing on Thursday its acquisition of early-stage biotech Celsius Therapeutics for $250 million in cash. This move aims to strengthen AbbVie’s longer-term prospects in inflammatory bowel...
by John Conrad | Jun 13, 2024 | NewsBrief
Inflammatory Bowel Disease (IBD) affects millions of people worldwide, causing chronic inflammation in the digestive tract and leading to debilitating symptoms. Current therapies often fail to provide adequate relief for many patients, highlighting the urgent need for...
by John Conrad | May 24, 2024 | Member News
AbbVie announced today that it has completed its previously disclosed acquisition of Landos Biopharma, Inc. With this transaction now closed, Landos and its lead investigational asset NX-13 for inflammatory bowel disease (IBD) have become part of AbbVie’s...
